Asgard Therapeutics is a Swedish private biotech company advancing cancer immunotherapies by pioneering in vivo direct reprogramming approaches to reinstate tumor immunogenicity. Founded as a spin-off from Lund University, Asgard builds on the discovery of a combination of reprogramming factors that induces professional antigen presentation. Once applied to cancer cells, it forces them to present their own antigens, inducing strong and personalized anti-tumor immunity. Supported by €9M in non-dilutive funding, Asgard achieved proof-of-principle and developed a robust IP strategy encompassing 29 patents over 5 families. In October 2021, Asgard closed a seed round of €6M co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, to complete the proof-of-concept for its lead gene therapy program. The leadership team is composed of the scientific co-founders with extensive experience in reprogramming technologies, Dr. Cristiana Pires (CEO), Prof Filipe Pereira (Head of Innovation), and Dr. Fabio Rosa (Head of Research), now complemented by Dr Alan Griffith (CDO, gene therapy expert), and Jan K Villadsen (Head of Finance). Martin Bonde chairs the board of directors, with more than 25+ years of executive and commercial experience. Asgard’s team is also supported by an experienced SAB, which includes Joshua Brody, Mount Sinai New York.